Statins and lipoprotein(a); facing the residual risk

Eur J Prev Cardiol. 2022 May 5;29(5):777-778. doi: 10.1093/eurjpc/zwab178.

Author

Gal Tsaban^{1

2}

Affiliations

¹ Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
² Department of Cardiology, Heart Institute, Rager Av. 101, Beersheba, 84101, Israel.

PMID: 34904162
DOI: 10.1093/eurjpc/zwab178

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Lipoprotein(a)

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoprotein(a)